(Q35567255)

8 August 2017

1 reference

title

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias (English)

1 reference

antineoplastic resistance

8 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576846

24 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206942

24 March 2024

author name string

Neil P. Shah

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576846

24 March 2024

Charles L. Sawyers

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14576846

24 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

8 August 2017

20 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14576846

full work available at URL

24 March 2024

https://www.nature.com/articles/1206942.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1038/SJ.ONC.1206942

https://www.nature.com/articles/1206942

24 March 2024

1 reference

DOI

https://api.crossref.org/works/10.1038/SJ.ONC.1206942

24 March 2024

1 reference

8 August 2017

22

1 reference

8 August 2017

7389-7395

1 reference

8 August 2017

47

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206942

8 August 2017

0 references

cites work

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206942

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

1 reference

Dimensions Publication ID

8 August 2017

0 references

1 reference